Latest Earnings Results:
Estimated EPS
---
Reported EPS
---
Surprise
---
Estimated Rev
---
Reported Rev
---
Surprise
---
For the third fiscal quarter of 2026, Anavex reported net income of $7.8M, or $0.08 per share, and held cash and cash equivalents of $118.3M as of June 30, 2026.
Bullish Takeaway
Anavex advanced regulatory submissions across its Alzheimer’s, Rett syndrome, and Fragile X programs, while maintaining $118.3M in cash and cash equivalents expected to fund operations into mid to late fiscal 2028.
Bearish Takeaway
Anavex faces delayed Form 10-Q filings impacting Nasdaq compliance, executive termination litigation risks, one-off expense recoveries distorting profitability, and the decision not to pursue a European Phase 3 Alzheimer's study at this time.
Generated by Stocktwits using AI and company-reported earnings data. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|